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Background. Human immunodeficiency virus (HIV) infection is a recognized risk factor for stroke among young populations, 
but the exact mechanisms are poorly understood. We studied the clinical, radiologic, and histologic features of HIV-related ischemic 
stroke to gain insight into the disease mechanisms.
Methods. We conducted a prospective, in-depth analysis of adult ischemic stroke patients presenting to Queen Elizabeth Central 
Hospital, Blantyre, Malawi, in 2011.
Results. We recruited 64 HIV-infected and 107 HIV-uninfected patients. Those with HIV were significantly younger (P < .001) 
and less likely to have established vascular risk factors. Patients with HIV were more likely to have large artery disease (21% vs 10%; 
P < .001). The commonest etiology was HIV-associated vasculopathy (24 [38%]), followed by opportunistic infections (16 [25%]). 
Sixteen of 64 (25%) had a stroke soon after starting antiretroviral therapy (ART), suggesting an immune reconstitution–like syn-
drome. In this group, CD4+ T-lymphocyte count was low, despite a significantly lower HIV viral load in those recently started on 
treatment (P < .001).
Conclusions. HIV-associated vasculopathy and opportunistic infections are common causes of HIV-related ischemic stroke. 
Furthermore, subtypes of HIV-associated vasculopathy may manifest as a result of an immune reconstitution–like syndrome after 
starting ART. A better understanding of this mechanism may point toward new treatments.
Keywords. stroke; vasculopathy; HIV; Africa; immune reconstitution syndrome.
 
Stroke incidence in low- to middle-income countries is increas-
ing, especially in young populations [1]. In many of these regions, 
human immunodeficiency virus (HIV) is prevalent, and younger 
populations are more likely to have infectious causes of stroke [2].
We recently showed that HIV infection makes a major con-
tribution to the overall stroke burden (population attributable 
fraction [PAF] = 15%) in Malawi [2]. It was the second leading 
risk factor overall (behind hypertension), and the most important 
among young stroke patients (PAF = 42%). Starting antiretroviral 
therapy (ART) appeared to contribute to stroke risk in the very 
immunosuppressed, but the mechanism of this is unknown [2]. 
Previous reports have shown that opportunistic infections, coagu-
lopathy, and cardiothromboembolism are important etiologies to 
consider [3]. In addition, HIV infection may directly lead to HIV-
associated vasculopathy via inflammatory intermediaries [4]. 
The term “vasculopathy” is defined as intimal hyperplasia more 
than expected for age, and thus encompasses several pathologic 
phenotypes of stroke found in HIV infection, including (1) HIV-
associated accelerated atherosclerosis; (2) nonatherosclerotic vas-
culopathy (patients have nonvasculitic abnormalities, with intimal 
hyperplasia that can progress to stenosis or aneurysmal dilatation); 
(3) HIV-associated vasculitis; and (4) small vessel disease [5]. Our 
understanding of the pathologic mechanisms of these phenotypes 
is incomplete. We have previously described more detailed clin-
icopathologic classification of HIV-associated vasculopathy [5].
Here we report the clinical, laboratory, radiologic, and 
autopsy features of HIV ischemic stroke patients, explore how 
they differ from the non-HIV ischemic stroke population, and 
consider the mechanisms of stroke among those starting ART.
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METHODS
Participants
The study was conducted at the Queen Elizabeth Central 
Hospital, Blantyre, Malawi; a large government hospital for 
much of Southern Malawi. The national prevalence of HIV 
in adults is 10.6% but higher (20%) in Blantyre [6]. Adults 
(≥18 years of age) who presented to the hospital within 7 days 
of symptom onset, and met the World Health Organization case 
definition of stroke—“a clinical syndrome consisting of rapidly 
developing clinical signs of focal (or global in case of coma) 
disturbance of cerebral function lasting >24 hours or leading 
to death with no apparent cause other than a vascular origin” 
[7]—were recruited to the study between February 2011 and 
April 2012 (Figure 1).
300 Suspected Stroke cases
(95 HIV positive, 201 HIV negative, 4 unknowns)
Feb 2011 – Apr 2012
MRI imaging
Ischemic stroke cases n=171
64 HIV-related Ischemic
stroke
Etiological classification
HIV-associated vasculopathy
Opportunistic infection
Cardioembolism
Coagulopathy
Antiphospholipid syndrome
Cryptogenic* stroke
Multifactorial
Inconclusive
24 (38)
16 (25)
4 (6)
6 (9)
11 (17)
1 (2)
2 (3)
Varicella Zoster Virus [VZV] (9)
Syphilis (3)
Mycobacterium Tuberculosis [MTB] (4)
Atherosclerosis [AS] (7)
Non-Atherosclerosis [Non-AS] (7)
Small vessel disease [SVD] (1)
Vasculitis [VA] (9)
4
Confirmed Probable
6
1
1
9
1
3
4
0
−
−
−
3
1
0
8
3
0
6
−
−
−
No. (%) Certainty of  diagnosis
107 HIV-negative Ischemic
stroke
Trial of  Org 10172 in Acute Stroke Treatment (TOAST) classification
HIV etiology stroke classification
MRI not performed n=35
(4 HIV positive, 30 HIV negative, 1
unknown)
Stroke mimic n=50
(17 HIV positive, 30 HIV negative,
3 unknowns)
Hemorrhagic stroke n=44
(10 HIV positive, 34 HIV negative)
Figure 1. Selection procedure and classification of cases. *Noninvasive or invasive angiography has not been done and therefore the subcategory of “cryptogenic embo-
lism” and “other cryptogenic” cannot be determined. Abbreviations: HIV, human immunodeficiency virus; MRI, magnetic resonance imaging.
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Procedure and Etiological Definitions
Clinical features and potential vascular risk factors (ie, age, sex, 
family history, ART use, hypertension, diabetes, hypercholes-
terolemia, acute infection, abdominal obesity, alcohol, smoking, 
substance use, and previous stroke/transient ischemic attack) 
were recorded. Stroke severity at baseline was assessed with 
the National Institutes of Health Stroke Scale, and performed 
within 7 days of symptom onset [8, 9]. Evidence of peripheral 
vascular disease was determined by measuring ankle brachial 
index using a handheld vascular Doppler (HI Dop, Ana Wiz 
Ltd, United Kingdom) [10]. Magnetic resonance imaging of the 
brain was performed within 7  days of admission. The defini-
tions for risk factors, severity of stroke, and imaging protocol 
were previously reported [2].
Investigations included full blood count, total cholesterol, 
random glucose, HIV-1 serology and viral load, and CD4+ 
T-lymphocyte count (CD4+ count) using previously described 
methods [2]. HIV-1 RNA load was measured using the Hologic 
Aptima HIV-1 Quant Dx assay (Hologic Inc, Manchester, 
United Kingdom). This sensitive assay has a lower limit of quan-
titation (LLOQ) of 30 copies/mL and a limit of detection of 13 
copies/mL. Antiphospholipid syndrome diagnostics (anticar-
diolipin antibody, lupus anticoagulant, anti-β2 –glycoprotein 1; 
Cambridge Life Sciences, Cambridgeshire, United Kingdom), 
and specific infection screening—(1) serum syphilis trepone-
mal immunoassay plus agglutination test and nontreponemal 
tests, and, if positive, cerebrospinal fluid (CSF) venereal dis-
ease research laboratory test, and (2) monoclonal intrathecal 
varicella zoster (VZV) antibody determination [11]—were not 
done locally and thus were performed using standard proto-
cols, at the hematology department, Royal Liverpool Hospital, 
and Public Health England, respectively. All blood cultures 
and CSF diagnostics (ie, microscopy, biochemistry, India ink 
and acid-fast bacilli stains, cryptococcal antigen, standard bac-
terial culture, Mycobacterium tuberculosis [TB] culture) were 
performed locally at the Malawi-Liverpool-Wellcome Trust 
(MLW) laboratory. MLW laboratory participates in interna-
tionally recognized quality control programs including the 
UK National External Quality Assessment Service and the 
South African National Health Laboratory Service scheme. 
Chest radiography, electrocardiography, carotid/vertebral 
duplex ultrasonography, and echocardiography were also per-
formed. When possible, a brain-only autopsy was performed 
in deceased HIV-infected patients. Brain tissue was stored in 
10% formalin and processed at the University of Edinburgh, 
United Kingdom. The tissue sections were stained with hema-
toxylin and eosin and Ziehl-Neelsen stain. Additional staining 
included p24 antigen (for HIV) and CD8, CD68, and CD3 
antibodies (for inflammation). The results were interpreted by 
a neuropathologist and general pathologist with expertise in 
HIV infection. Although the pathologists were not blinded to 
the HIV status, a consensus had to be reached among these 
senior pathologists, with the third (HIV pathologist) arbitrat-
ing when needed.
The etiology was determined using the Trial of Org 10172 in 
Acute Stroke Treatment (TOAST) classification (Figure 1). To 
expand the other determined and undetermined category and 
handle multiple etiologies in the HIV cohort, we also used the 
HIV Etiology for Ischemic Stroke classification, as described 
previously (Figure 1). The physician who determined the final 
diagnosis was blinded to ART status, degree of immunosup-
pression, and HIV viral burden.
Ethical Consideration
The study was approved by the Liverpool School of Tropical 
Medicine, United Kingdom, and the College of Medicine 
Research Ethics Committee, University of Malawi. All partic-
ipants or guardians gave written informed consent.
Statistical Analysis
Discrete variables were reported as absolute counts and per-
centages. Continuous variables are shown as the median with 
interquartile range (IQR). HIV RNA load below the LLOQ was 
coded as 30 copies/mL (the assay’s quantification limit). This 
was then log-transformed to compare the median HIV RNA 
load across specified groups. Contingency tables comparing (1) 
HIV infected/uninfected and (2) HIV etiology for stroke classi-
fication were analyzed with Fisher 2-sided exact test. Kruskal-
Wallis nonparametric analysis of variance was used to compare 
continuous variables.
Statistical analyses were done with Stata software version 11.2 
and GraphPad Prism version 6 (GraphPad Software). A signifi-
cance level of <.05 was used throughout.
RESULTS
Three hundred patients with suspected stroke were screened 
during the study period, of whom 171 (64 HIV infected and 107 
HIV uninfected) had ischemic strokes and met the entry crite-
ria (Figure 1). Table 1 describes the demographic and clinical 
characteristics of the HIV-infected and -uninfected individuals. 
The 64 HIV-infected ischemic stroke cases form the basis of this 
study. Of these, 26 (40%) were on ART and 4 had brain autopsy.
Comparison Between HIV-Infected and -Uninfected Patients
Compared with the HIV-uninfected patients, the HIV-infected 
patients were significantly younger (median age, 40 years vs 66 
years; P < .001) and less likely to be hypertensive (42% vs 83%; 
P < .001; Table 1). Other vascular risk factors, including diabe-
tes, hypercholesterolemia, and being a smoker, were more com-
mon in patients who were HIV uninfected. Imaging analysis 
showed that basal ganglia ischemia occurred more often with 
HIV ischemic stroke (68% vs 42%; P < .001). Using the TOAST 
classification, the other determined and undetermined etiologic 
category were common in both groups. However, for the bet-
ter characterized categories, large artery disease had a different 
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distribution and occurred more frequently in the HIV-infected 
group (21% vs 10%; Table 1).
Etiology of HIV-Related Ischemic Stroke
HIV-associated vasculopathy (ie, accelerated atherosclerosis, 
nonatherosclerotic vasculopathy, HIV-associated vasculitis, 
and small vessel disease) was the commonest etiology (38%), 
followed by opportunistic infections (25%); the latter included 
VZV, TB, and syphilis (Table 2). Although VZV was the most 
frequent infection, it was often not clinically obvious, with only 
3 of 9 (30%) having had a vesicular rash in the corresponding 
cranial distribution within 6 months of their stroke. No patient 
had evidence of occult cryptococcal disease. Despite a compre-
hensive workup, a specific cause was not determined in the 17% 
with cryptogenic stroke.
Age (P  <  .001), CD4+ count (P  =  .031), and ART status 
(P  =  .048) differed significantly for the different etiologic 
groups. For example, patients with nonatherosclerotic vas-
culopathy, HIV-associated vasculitis, opportunistic infec-
tion, and cryptogenic stroke had a median age ≤45  years (ie, 
young stroke) whereas those with atherosclerotic vasculopa-
thy and cardiothromboembolism were older (Table  2). In the 
Table 1. Clinical, and Radiologic Characteristics of Ischemic Stroke in Human Immunodeficiency Virus–Infected and –Uninfected Cohorts
Characteristic HIV Infected (n = 64) HIV Uninfected (n = 107) P Valuea
Median age, y (IQR) 40 (32–51) 66 (53–77) <.001
Male sex 29 (45) 49 (46) 1.000
Family history 9 (14) 17 (17) .403
Hypertension 27 (42) 89 (83) <.001
Diabetes 2 (3) 14 (13) .032
Hypercholesterolemia 4 (7) 10 (10) .510
Current smoker 6 (9) 26 (24) .016
Recent infection 12 (19) 8 (8) .082
Alcohol intake 13 (21) 14 (13) .379
Cannabis use 1 (2) 3 (3) 1.000
Obesity .496
 Tertile 1 14 (22) 17 (16)
 Tertile 2 23 (37) 33 (31)
 Tertile 3 26 (41) 56 (53)
Median ankle brachial index (IQR) 1.01 (0.96–1.01) 1.01 (0.94–1.06) .946
Previous TIA 4 (6) 7 (7) .274
Previous stroke 4 (6) 15 (14) .244
Radiologic characteristics
 Acute/subacute MRI lesions
  Cerebral cortexb 39 (68) 61 (66) .721
  Cerebellum 4 (7) 3 (3) .297
  Brainstem 6 (11) 9 (10) .866
  Basal ganglia 39 (68) 39 (42) .002
 Periventricular white matter 
disease
24 (42) 33 (36) .418
 Otherc 1 (2) 2 (2) .162
 >1 focal lesion 12 (21) 6 (8) .034
Stroke characteristics
 Median NIH stroke scale (IQR) 12 (8–14) 11 (7–18) .813
Etiology of stroke (TOAST) <.001
 Large artery disease 14 (21) 14 (10)
 Cardiothromboembolism 4 (6) 13 (9)
 Small vessel disease 1 (1)  3 (2)
 Stroke of other determined caused 31 (46) 15 (11)
 Stroke of undetermined cause 18 (27) 92 (67)
Hospital fatality 11 (17) 10 (9) .152
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: HIV, human immunodeficiency virus; IQR, interquartile range; MRI, magnetic resonance imaging; NIH, National Institutes of Health; TIA, transient ischemic attack; TOAST, Trial 
of Org 10172 in Acute Stroke Treatment.
aCategorical variables were analyzed with Fisher 2-sided exact test. Kruskal-Wallis nonparametric analysis of variance was used to compare continuous variables.
bCerebral cortex includes frontal, temporal, occipital, and parietal lobe.
cCorpus callosum, hypothalamus, pituitary, craniocervical junction.
dStroke of other determined cause in the HIV-uninfected group includes probable antiphospholipid syndrome (7), syphilis (4), varicella zoster (2), tuberculosis (1), probable vasculitis (1).
eSee Table 2 for HIV-associated stroke.
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most immunosuppressed patients whose median CD4+ count 
was <200 cells/μL, HIV-associated vasculitis, opportunistic 
infections, and antiphospholipid syndrome were the most fre-
quently found etiologies. The ART status differed significantly 
for these patients: 67% of those with HIV-associated vasculitis 
had started ART in the 6 months prior to their stroke; in con-
trast, only 33% of those with antiphospholipid syndrome and 
19% of those with opportunistic infections had recently started 
ART (Table  2). Furthermore, blood HIV viral load differed 
across these groups, being high (median, 3.5 and 4.7 copies/mL, 
respectively) in patients with opportunistic infections and anti-
phospholipid syndrome, in contrast to being below the lower 
limit of quantitation, in patients with HIV-associated vasculi-
tis. There were no significant differences in measured CSF cell 
count and biochemistry across the groups.
HIV-Associated Vasculopathy
The HIV-associated vasculopathy subtypes included accelerated 
atherosclerosis (n  =  7), nonatherosclerosis (n  =  7), and HIV-
associated vasculitis (n = 9); the median age for these patients 
was 60  years, 33  years, and 35  years, respectively (Table  2). 
Because there was only 1 case of small vessel disease, this was 
not included in the detailed analysis. The various types of HIV-
associated vasculopathy differed by ART status and CD4+ count 
(Table  2); for example, no patient with atherosclerotic vascu-
lopathy had started ART in the last 6 months, compared with 
43% of the nonatherosclerotic and 67% of the HIV-associated 
vasculitis subtypes.
At autopsy (Supplementary Figure  1), 2 patients showed 
extensive atherosclerosis in all sized vessels (the images were 
consistent); 1 was on ART and young (50 years), with no estab-
lished vascular risk factors. Although the other patient was 
older (74 years), not on ART, with a new diagnosis of hyperten-
sion; the degree of atherosclerosis was marked. All patients with 
HIV-associated vasculitis had a median CD4+ count of <200 
cells/μL, and HIV-1 RNA was below the LLOQ; this differed 
from those with nonatherosclerotic and atherosclerotic vascu-
lopathy (Table 2).
Initiating ART
Sixteen of 64 (25%) patients had an ischemic stroke within 
6 months of starting ART. Ten (63%) of these recent ART initi-
ators had a stroke within 1 month of starting ART. The median 
age, CD4+ count, and blood HIV RNA load were 37 years (IQR, 
31–47), 122 (IQR, 73–237) cells/μL, and 1.5 (IQR, 0.7–2.1) log10 
copies/mL, respectively. We explored established risk factors for 
immune reconstitution inflammatory syndrome (IRIS), such as 
anemia, low CD4+ count, and a drop in HIV RNA load. Patients 
recently started on ART had the lowest median CD4+ count 
(122 [IQR, 73–236] cells/μL compared with 159 [IQR, 65–279] 
cells/μL in patients never started on ART, and 295 [IQR, 192–
455] cells/μL in patients on ART for ≥6  months (P  =  .107). Ta
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Recent ART initiators were also more anemic (median hemo-
globin, 11.0 [IQR, 9.0–12.0] g/dL) and had lower viral loads 
than the other ART categories (Figure  2). The distribution of 
etiologies differed substantially by ART status group (P < .048; 
Figure 1), in keeping with the epidemiologic evidence that the 
first 6 months of ART is a high risk period for stroke [2]. Within 
this time period, HIV-associated vasculopathy (specifically 
HIV-associated vasculitis [n  =  6] and nonatherosclerotic vas-
culopathy [n = 3]) was the commonest diagnosis (56%). Brain 
histologic material from 2 IRIS-like cases revealed TB meningi-
tis and HIV-associated vasculitis (Figure 3).
DISCUSSION
This in-depth analysis of a large cohort of patients shows that 
ischemic stroke in people with HIV infection is distinct from 
the non-HIV population, with a younger age of onset and a 
different risk factor profile. Based on clinical, radiologic, and 
autopsy analysis, we found that HIV-associated vasculopathy 
and opportunistic infections were the most common etiologies. 
Among patients with HIV-associated vasculopathy, the 3 sub-
types (ie, accelerated atherosclerosis, nonatherosclerosis, and 
vasculitis) appear to have different risk factors. Importantly, 
most ischemic stroke patients with nonatherosclerotic vascu-
lopathy or HIV-associated vasculitis had recently started on 
ART, which is suggestive of IRIS.
IRIS occurs during immune system recovery after an immu-
nodeficient state. It is associated with a rapid decline (of ≥2 
logs) in HIV viral load, a low nadir and then rising CD4+ count 
following ART introduction, and anemia [12–15]. The mech-
anism, although widely believed to be driven by infiltration of 
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Figure 2. Clinical, radiologic, and laboratory features among those starting antiretroviral therapy (ART). A, Etiology by ART status shows human immunodeficiency virus 
(HIV)–associated vasculopathy to be the most common etiology among those starting ART. B, Radiologic examples of HIV-associated vasculopathy found among those 
starting ART: ID 32—diffusion-weighted (left) and fluid attenuated inversion recovery (FLAIR) (middle) sequences show a left middle cerebral artery infarct, while Doppler of 
the left common carotid artery (right) illustrates underlying concentric stenosis (≥70%) extending into the bulb; ID 278—middle cerebral artery infarct on diffusion-weighted 
(left) and T2-weighted (right) sequences; ID 46 and 85—diffusion-weighted and FLAIR sequences show multifocal ischemic lesions in the basal ganglia and cortices. C, Risk 
factors of immune reconstitution inflammatory syndrome compared across the ART groups. Kruskal-Wallis nonparametric analysis of variance was used to compare contin-
uous variables across the ART status groups. *Noninvasive or invasive angiography has not been done and therefore the subcategory of “cryptogenic embolism” and “other 
cryptogenic” cannot be determined. Abbreviations: APS, antiphospholipid syndrome; ART, antiretroviral therapy; CTE, cardiothromboembolism; HIV, human immunodeficiency 
virus; IRIS, immune reconstitution inflammatory syndrome; O.I., opportunistic infection.
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active T cells, still remains unclear [14]. In our cohort, those 
presenting with a stroke after recently starting ART showed 
some risk factors for IRIS [16]. However, although HIV viral 
loads appeared to be largely suppressed, we did not see the 
higher CD4+ counts and therefore evidence of immune recon-
stitution typically associated with IRIS. This immunovirologic 
discordance was unexpected and suggests persistent immune 
dysregulation. Arguably, cell counts may not wholly reflect 
function and as evidenced by viral suppression, there may have 
been immune recovery even in the absence of an increased 
CD4+ count [15]. Such immune-virologic discordance was 
recently implicated in non-AIDS complications, and thus this 
merits further investigation [17].
Patients diagnosed with HIV-associated vasculitis were 
highly immunosuppressed and thus it is plausible that vessel 
wall inflammation was driven by an undiagnosed opportunis-
tic infection. Tuberculosis and cryptococcus, for example, are 
frequent triggers of central nervous system (CNS) IRIS [18]. 
However, patients with confirmed opportunistic infections 
tended not to be on ART, and had a correspondingly high 
HIV viral load. Furthermore, TB was only identified in 6% of 
ischemic stroke and we did not detect cryptococcal disease. 
Of our 4 patients who had autopsy following ischemic stroke, 
1 patient with characteristic features of endarteritis obliterans 
was diagnosed clinically and confirmed at autopsy with TB 
meningitis. Nonetheless, our results are more consistent with 
CNS-IRIS triggered by an immune response to HIV viral anti-
gens per se [14]. The postulated mechanisms include immune 
response directed at residual HIV virus in the CNS, persistent 
release of HIV-Tat protein from HIV-infected cells despite con-
trol of viral replication, and inflammatory responses directed 
against self-antigens [14].
Patients with atherosclerotic vasculopathy were not as 
immunosuppressed as patients with other subtypes of HIV-
associated vasculopathy. The relatively young patient (ID: 218), 
who was on ART for >6  months, showed histologic evidence 
of extensive atherosclerosis in the absence of other vascular 
risk factors (Supplementary Figure  1). At a population level, 
studies in high-income countries have consistently shown 
that HIV-infected individuals have a substantially high risk of 
stroke, roughly equivalent to that of general population cohorts 
10–20 years older than themselves [19]. This is despite exposure 
ID 219: HIV-associated vasculitis after starting ART ID 219: TB meningitis with endarteritis obliterans after starting
ART
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Figure 3. Radiohistologic characteristics in patients presenting with human immunodeficiency virus (HIV)–associated vasculitis vs vasculitis related to tuberculous men-
ingitis after starting antiretroviral therapy (ART). A–E, A-32 year-old (5 months pregnant) woman on ART for <6 months with an acute right arm monoparesis, dysphasia, and 
headache. Her CD4+ count was 175 cells/μL and HIV blood and cerebrospinal fluid (CSF) viral load were undetected on admission. Mild pleocytosis (white cell count was 10 
cells/μL), moderately elevated protein (1.6 mg/L), and a glucose ratio of 0.48 was found on CSF examination. A–C, Magnetic resonance imaging (MRI) confirmed an acute 
middle cerebral artery infarct. D and E, Histopathology showed multiple infarction of the cortical laminar type, marked periarteritis with foci of muscle necrosis, present in 
all sized arteries. There was lymphocytic meningitis but no granuloma or caseation or giant cells typical of tuberculous meningitis. There were no cytomegalovirus inclusion 
bodies, and varicella zoster intrathecal immunoglobulin G was negative. F–J, A 34-year-old woman on ART for <6 months with an acute right arm weakness, headache, neck 
ache, and fever. CD4+ count was 128 cells/μL and HIV blood and CSF viral load on admission were 1.48 and 3.22 log10 copies/mL, respectively. There was no CSF pleocytosis 
but a markedly elevated protein of 16.6 mg/L and CSF-to-glucose ratio of 0.28. Brain MRI confirmed an acute infarct of the basal ganglia with mild hydrocephalus. I and 
J, Histopathology showed endarteritis obliterans of the small arteries with and a recent infarct of the basal ganglia. There was widespread meningeal inflammation with 
confluent and discrete tuberculoid granulomas, typical caseating necrosis, and Langhans giant cells. There were superficial Rich foci (ie tuberculous cerebritis adjacent to the 
meninges). Acid-fast bacilli stain was negative but histology was characteristic of tuberculous meningitis. Abbreviations: ART, antiretroviral therapy; DW, diffusion weighted; 
HIV, human immunodeficiency virus; TB, tuberculosis.
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to opportunistic infections being far lower, and the additive 
risk of ART toxicity and HIV/ART-induced metabolic dysreg-
ulation (eg, hyperlipidemia) being accounted for [4, 19]. HIV 
could have a causal role in this disease mechanism, but this is 
still open to debate. However, there is growing evidence that 
HIV-related chronic inflammation even in well-suppressed 
HIV-infected individuals is linked to subclinical vasculopathy 
[4]. While HIV-associated vasculopathy appears to be more 
common in sub-Saharan Africa compared with elsewhere, the 
atherosclerotic and cryptogenic subtypes are likely to become 
the predominant subtypes as the HIV population ages and the 
disease stabilizes, and thus, warrants further investigation.
There were some limitations to the study; for example, we did 
not screen for sickle cell disease. However, although commonly 
associated with stroke elsewhere in sub-Saharan Africa, the 
prevalence of sickle cell disease in Malawi is low (<2%) and thus 
unlikely to have made a major contribution [20]. The absence 
of cerebral angiography limited our ability to refine the diagno-
sis of the cryptogenic group and thus further subdivide them 
into cardiac embolic or noncardiac embolic causes. Indeed, the 
latter could have represented undiagnosed HIV-associated vas-
culopathy. Furthermore, nonatherosclerotic vasculopathy and 
HIV-associated vasculitis could be manifestations of the same 
disease process at different stages of HIV infection, It is possi-
ble that the hospital recruitment may have been biased against 
milder cases in the community. It is also possible that the risk of 
stroke seen in those starting ART may be related to being sick 
and not ART itself, although difficult to tease out; our proposed 
mechanism of IRIS is not dissimilar to other infections, in the 
very immunosuppressed, such as TB and cryptococcal CNS 
infection [15, 21]. Finally, CNS-IRIS is associated with a poor 
prognosis and is often fatal within days to weeks if untreated, 
leaving the possibility that ischemic stroke among those start-
ing ART could have been underestimated if patients died before 
hospital admission [14, 18].
HIV-associated vasculopathy and opportunistic infec-
tions are common causes of HIV-related ischemic stroke. 
Furthermore, subtypes of HIV-associated vasculopathy may 
manifest as a result of an immune reconstitution-like syndrome 
after starting ART. This study highlights the different pheno-
types of HIV-associated vasculopathy and ties in with emerging 
data on neuroinflammation before and after HIV infection. Our 
understanding of the underlying mechanism and the role that 
HIV plays is incomplete, especially on better treated cohorts 
with cryptogenic stroke, and possibly “HIV-associated” athero-
sclerosis. This highlights the importance for future mechanistic 
studies to underpin the pathogenesis of these various subtypes 
and, in time, pave the way for appropriate interventions.
Supplementary Data
Supplementary materials are available at The Journal of Infectious 
Diseases online. Consisting of data provided by the authors to 
benefit the reader, the posted materials are not copyedited and 
are the sole responsibility of the authors, so questions or com-
ments should be addressed to the corresponding author.
Notes
Acknowledgments. We thank Malcolm Molyneux for 
his helpful input in developing the autopsy protocol; Kevin 
Brown, David Brown, and Catherine Ison from Public Health 
England for their help with VZV and syphilis diagnostics; and 
Colin Downey for his help with antiphospholipid syndrome 
diagnostics.
Author contributions. L. A. B., T. S., T. J. A., R. S. H., E. L. 
C., and M.  D. C.  designed the study. L.  A. B.  performed the 
research, did the literature search, analyzed the data, and wrote 
the first draft of the paper. T. S., M. D. C., R. S. H., E. L. C., E. J., 
and S. L.  revised the first draft of the paper. I. T., E.  J., K. C., 
H. M., S. K., C. S., S. L., S. K., and M. H. performed the research. 
T. S. and T. J. A. supervised the conduct of the study. All authors 
contributed to critical revision of the manuscript.
Financial support. This work was supported by a Clinical 
PhD Fellowship from The Wellcome Trust, Great Britain (to 
L.  A. B.) and a United Kingdom Medical Research Council 
Fellowship (to T.  S.), and The National Institute for Health 
Research Health Protection Research Unit in Emerging and 
Zoonotic Infections (to T. S.). The Malawi-Liverpool-Wellcome 
Trust Clinical Research Programme is supported by a Strategic 
Award from The Wellcome Trust.
Potential conflicts of interest. M. C. has received lecture/meet-
ing fees from AbbVie. All other authors report no potential con-
flicts. All authors have submitted the ICMJE Form for Disclosure 
of Potential Conflicts of Interest. Conflicts that the editors consider 
relevant to the content of the manuscript have been disclosed.
References
 1. Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global 
and regional burden of stroke during 1990–2010: findings 
from the Global Burden of Disease Study 2010. Lancet 
2014; 383:245–54.
 2. Benjamin LA, Corbett EL, Connor MD, et al. HIV, antiret-
roviral treatment, hypertension, and stroke in Malawian 
adults: a case-control study. Neurology 2016; 86:324–33.
 3. Tipping B, de Villiers L, Wainwright H, Candy S, Bryer A. 
Stroke in patients with human immunodeficiency virus 
infection. J Neurol Neurosurg Psychiatry 2007; 78:1320–4.
 4. Benjamin LA, Bryer A, Emsley HC, Khoo S, Solomon T, 
Connor MD. HIV infection and stroke: current perspec-
tives and future directions. Lancet Neurol 2012; 11:878–90.
 5. Benjamin LA, Bryer A, Lucas S, et  al. Arterial ischemic 
stroke in HIV: defining and classifying etiology for research 
studies. Neurol Neuroimmunol Neuroinflamm 2016; 
3:e254.
Downloaded from https://academic.oup.com/jid/article-abstract/216/5/545/4002646
by London School of Hygiene & Tropical Medicine user
on 18 January 2018
Etiology of HIV Ischemic Stroke • JID 2017:216 (1 September) • 553
 6. Choko AT, Desmond N, Webb EL, et  al. The uptake and 
accuracy of oral kits for HIV self-testing in high HIV prev-
alence setting: a cross-sectional feasibility study in Blantyre, 
Malawi. PLoS Med 2011; 8:e1001102.
 7. Hatano S. Experience from a multicentre stroke regis-
ter: a preliminary report. Bull World Health Organ 1976; 
54:541–53.
 8. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. 
Classification and natural history of clinically identifiable 
subtypes of cerebral infarction. Lancet 1991; 337:1521–6.
 9. Brott T, Adams HP Jr, Olinger CP, et  al. Measurements 
of acute cerebral infarction: a clinical examination scale. 
Stroke 1989; 20:864–70.
 10. Hirsch AT, Haskal ZJ, Hertzer NR, et  al. ACC/AHA 2005 
practice guidelines for the management of patients with 
peripheral arterial disease (lower extremity, renal, mesen-
teric, and abdominal aortic): a collaborative report from 
the American Association for Vascular Surgery/Society for 
Vascular Surgery, Society for Cardiovascular Angiography 
and Interventions, Society for Vascular Medicine and 
Biology, Society of Interventional Radiology, and the 
ACC/AHA Task Force on Practice Guidelines (Writing 
Committee to Develop Guidelines for the Management of 
Patients With Peripheral Arterial Disease): endorsed by the 
American Association of Cardiovascular and Pulmonary 
Rehabilitation; National Heart, Lung, and Blood Institute; 
Society for Vascular Nursing; TransAtlantic Inter-Society 
Consensus; and Vascular Disease Foundation. Circulation 
2006; 113:e463–654.
 11. Winchester SA, Brown KE. A woman with suspected sub-
acute sclerosing panencephalitis (SSPE). J Clin Virol 2011; 
50:93–5.
 12. Haddow LJ, Easterbrook PJ, Mosam A, et  al. Defining 
immune reconstitution inflammatory syndrome: evalua-
tion of expert opinion versus 2 case definitions in a South 
African cohort. Clin Infect Dis 2009; 49:1424–32.
 13. Haddow LJ, Moosa MY, Mosam A, Moodley P, Parboosing 
R, Easterbrook PJ. Incidence, clinical spectrum, risk fac-
tors and impact of HIV-associated immune reconstitution 
inflammatory syndrome in South Africa. PLoS One 2012; 
7:e40623.
 14. Johnson TP, Nath A. New insights into immune reconstitu-
tion inflammatory syndrome of the central nervous system. 
Curr Opin HIV AIDS 2014; 9:572–8.
 15. Haddow LJ, Colebunders R, Meintjes G, et al; International 
Network for the Study of HIV-Associated IRIS (INSHI). 
Cryptococcal immune reconstitution inflammatory syn-
drome in HIV-1-infected individuals: proposed clinical 
case definitions. Lancet Infect Dis 2010; 10:791–802.
 16. Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence 
and risk factors for immune reconstitution inflammatory 
syndrome during highly active antiretroviral therapy. AIDS 
2005; 19:399–406.
 17. Zoufaly A, Cozzi-Lepri A, Reekie J, et  al; EuroSIDA in 
EuroCoord. Immuno-virological discordance and the 
risk of non-AIDS and AIDS events in a large observa-
tional cohort of HIV-patients in Europe. PLoS One 2014; 
9:e87160.
 18. Bahr N, Boulware DR, Marais S, Scriven J, Wilkinson RJ, 
Meintjes G. Central nervous system immune reconstitu-
tion inflammatory syndrome. Curr Infect Dis Rep 2013; 
15:583–93.
 19. Sico JJ, Chang CC, So-Armah K, et  al; Veterans Aging 
Cohort Study. HIV status and the risk of ischemic stroke 
among men. Neurology 2015; 84:1933–40.
 20. Calis JC, Phiri KS, Faragher EB, et  al. Severe anemia in 
Malawian children. N Engl J Med 2008; 358:888–99.
 21. Meintjes G, Lawn SD, Scano F, et al; International Network 
for the Study of HIV-associated IRIS. Tuberculosis-
associated immune reconstitution inflammatory syndrome: 
case definitions for use in resource-limited settings. Lancet 
Infect Dis 2008; 8:516–23.
Downloaded from https://academic.oup.com/jid/article-abstract/216/5/545/4002646
by London School of Hygiene & Tropical Medicine user
on 18 January 2018
